Published in Eur J Nucl Med Mol Imaging on September 29, 2005
Multimodality imaging of the HER-kinase axis in cancer. Eur J Nucl Med Mol Imaging (2007) 1.23
Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence. Eur J Nucl Med Mol Imaging (2006) 1.06
A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue. Eur J Nucl Med Mol Imaging (2010) 1.04
Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses. Oncoimmunology (2013) 1.01
Radioimmunotherapy of solid tumors: searching for the right target. Curr Drug Deliv (2011) 0.96
Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody. Theranostics (2014) 0.91
Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts. Eur J Nucl Med Mol Imaging (2011) 0.90
Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules. Eur J Nucl Med Mol Imaging (2008) 0.86
Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels. Eur J Nucl Med Mol Imaging (2010) 0.84
(186)Re-maSGS-Z (HER2:342), a potential Affibody conjugate for systemic therapy of HER2-expressing tumours. Eur J Nucl Med Mol Imaging (2009) 0.83
Pre-Clinical Assessment of Lu-Labeled Trastuzumab Targeting HER2 for Treatment and Management of Cancer Patients with Disseminated Intraperitoneal Disease. Pharmaceuticals (Basel) (2011) 0.82
One target, different effects: a comparison of distinct therapeutic antibodies against the same targets. Exp Mol Med (2011) 0.79
Metallofullerene-nanoplatform-delivered interstitial brachytherapy improved survival in a murine model of glioblastoma multiforme. Bioconjug Chem (2012) 0.77
Evaluation of a maleimido derivative of CHX-A'' DTPA for site-specific labeling of affibody molecules. Bioconjug Chem (2008) 0.77
Direct comparison of 111In-labelled two-helix and three-helix Affibody molecules for in vivo molecular imaging. Eur J Nucl Med Mol Imaging (2011) 0.76
Dansylcadaverine inhibits internalization of 125I-epidermal growth factor in BALB 3T3 cells. J Biol Chem (1980) 5.24
Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol (2004) 2.66
A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice. Cancer Res (2004) 2.00
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol (2005) 1.99
HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer (2004) 1.79
Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. BJU Int (2005) 1.58
Role of HER2/neu in tumor progression and therapy. Cell Mol Life Sci (2004) 1.28
Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using (111)In-trastuzumab (Herceptin) Fab fragments. Nucl Med Biol (2005) 1.28
Radiometal labeling of immunoproteins: covalent linkage of 2-(4-isothiocyanatobenzyl)diethylenetriaminepentaacetic acid ligands to immunoglobulin. Bioconjug Chem (1991) 1.20
Conjugation with (111)In-DTPA-poly(ethylene glycol) improves imaging of anti-EGF receptor antibody C225. J Nucl Med (2001) 1.06
Tumour therapy with radionuclides: assessment of progress and problems. Radiother Oncol (2003) 1.02
Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol Immunother (2003) 0.95
A new therapeutic antibody masks ErbB2 to its partners. Cancer Cell (2004) 0.91
Biomarker conservation in primary and metastatic epithelial ovarian cancer. Gynecol Oncol (2000) 0.89
Future directions in radioimmunotherapy for B-cell lymphoma. Semin Oncol (2003) 0.75
Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res (2006) 2.46
Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. J Nucl Med (2010) 1.75
Flow cytometric in situ proximity ligation analyses of protein interactions and post-translational modification of the epidermal growth factor receptor family. Cytometry A (2009) 1.73
Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res (2007) 1.67
Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. BJU Int (2005) 1.58
Regional lung perfusion estimated by electrical impedance tomography in a piglet model of lung collapse. J Appl Physiol (1985) (2011) 1.54
Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry. J Nucl Med (2009) 1.54
Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res (2007) 1.40
Ventilation distribution studies comparing Technegas and "Gallgas" using 68GaCl3 as the label. J Nucl Med (2011) 1.39
111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J Nucl Med (2006) 1.32
First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule. J Nucl Med (2014) 1.31
Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy. Curr Opin Drug Discov Devel (2007) 1.30
EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases. Int J Oncol (2007) 1.28
Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain. J Biol Chem (2010) 1.27
On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. J Nucl Med (2009) 1.23
(99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors. Bioconjug Chem (2007) 1.22
Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule. J Mol Biol (2008) 1.19
Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount. Eur J Nucl Med Mol Imaging (2009) 1.16
Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors. J Nucl Med (2005) 1.16
In vivo evaluation of cysteine-based chelators for attachment of 99mTc to tumor-targeting Affibody molecules. Bioconjug Chem (2007) 1.13
Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake. Eur J Nucl Med Mol Imaging (2008) 1.06
Evaluation of ((4-hydroxyphenyl)ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody. Bioconjug Chem (2005) 1.06
Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence. Eur J Nucl Med Mol Imaging (2006) 1.06
Cellular studies of binding, internalization and retention of a radiolabeled EGFR-binding affibody molecule. Nucl Med Biol (2007) 1.06
Boron neutron capture therapy for glioblastoma multiforme: clinical studies in Sweden. J Neurooncol (2003) 1.05
A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue. Eur J Nucl Med Mol Imaging (2010) 1.04
In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics. Cancer Biother Radiopharm (2005) 1.03
Biodistribution of 211At labeled HER-2 binding affibody molecules in mice. Oncol Rep (2007) 1.02
Design of an optimized scaffold for affibody molecules. J Mol Biol (2010) 1.02
Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice. Eur J Nucl Med Mol Imaging (2006) 1.02
99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule. Eur J Nucl Med Mol Imaging (2007) 1.02
Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules. Bioconjug Chem (2007) 1.01
Kinetic determinations of molecular interactions using Biacore--minimum data requirements for efficient experimental design. J Mol Recognit (2005) 1.01
Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold. J Nucl Med (2010) 1.00
Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors. J Nucl Med (2006) 0.99
Development of EGF-conjugated liposomes for targeted delivery of boronated DNA-binding agents. Bioconjug Chem (2002) 0.99
Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography. Br J Haematol (2003) 0.99
Engineering of affibody molecules for therapy and diagnostics. Methods Mol Biol (2012) 0.98
Noise correlation in PET, CT, SPECT and PET/CT data evaluated using autocorrelation function: a phantom study on data, reconstructed using FBP and OSEM. BMC Med Imaging (2005) 0.98
Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer. Cancer Immunol Res (2013) 0.98
Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer. J Nucl Med (2011) 0.96
Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine. J Nucl Med (2009) 0.96
Elimination of stabilised hyaluronan from the knee joint in healthy men. Clin Pharmacokinet (2002) 0.95
Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification. J Nucl Med (2013) 0.95
Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification. PLoS One (2013) 0.94
Lessons on Tumour Response: Imaging during Therapy with (177)Lu-DOTA-octreotate. A Case Report on a Patient with a Large Volume of Poorly Differentiated Neuroendocrine Carcinoma. Theranostics (2012) 0.94
Update: affibody molecules for molecular imaging and therapy for cancer. Cancer Biother Radiopharm (2007) 0.93
Gefitinib induces epidermal growth factor receptor dimers which alters the interaction characteristics with ¹²⁵I-EGF. PLoS One (2011) 0.93
Engineering and characterization of a bispecific HER2 x EGFR-binding affibody molecule. Biotechnol Appl Biochem (2009) 0.92
Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules. Protein Eng Des Sel (2010) 0.91
Automated, high-resolution cellular retention and uptake studies in vitro. Appl Radiat Isot (2006) 0.91
Radionuclide molecular imaging using Affibody molecules. Curr Pharm Biotechnol (2010) 0.91
Circumventing the requirement of binding saturation for receptor quantification using interaction kinetic extrapolation. Nucl Med Commun (2011) 0.91
Cellular effects of HER3-specific affibody molecules. PLoS One (2012) 0.91
Imaging of insulinlike growth factor type 1 receptor in prostate cancer xenografts using the affibody molecule 111In-DOTA-ZIGF1R:4551. J Nucl Med (2011) 0.91
Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts. Eur J Nucl Med Mol Imaging (2011) 0.90
Deciphering complex protein interaction kinetics using Interaction Map. Biochem Biophys Res Commun (2012) 0.90
Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties. J Nucl Med (2011) 0.89
Minor changes in effective half-life during fractionated 177Lu-octreotate therapy. Acta Oncol (2011) 0.88
Labelling chemistry and characterization of [90Y/177Lu]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma. Int J Mol Med (2007) 0.88
Kinetic and affinity predictions of a protein-protein interaction using multivariate experimental design. J Biol Chem (2002) 0.88
[177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts. Cancer Res (2007) 0.87
Differences in radiosensitivity between three HER2 overexpressing cell lines. Eur J Nucl Med Mol Imaging (2008) 0.87
Generation and evaluation of bispecific affibody molecules for simultaneous targeting of EGFR and HER2. Bioconjug Chem (2012) 0.87
Blocking EGFR in the liver improves the tumor-to-liver uptake ratio of radiolabeled EGF. Tumour Biol (2010) 0.87
Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99mTc-labeled anti-HER2 Affibody molecules. Bioconjug Chem (2008) 0.87
Liver uptake of radiolabeled targeting proteins and peptides: considerations for targeting peptide conjugate design. Drug Discov Today (2012) 0.86
Evaluation of a maleimido derivative of NOTA for site-specific labeling of affibody molecules. Bioconjug Chem (2011) 0.86
HER-2--a possible target for therapy of metastatic urinary bladder carcinoma. Acta Oncol (2002) 0.86
Quantification of internalization of EGFR-binding Affibody molecules: Methodological aspects. Int J Oncol (2010) 0.85
HAHAHA, HEHEHE, HIHIHI, or HKHKHK: influence of position and composition of histidine containing tags on biodistribution of [(99m)Tc(CO)3](+)-labeled affibody molecules. J Med Chem (2013) 0.85
QSAR studies applied to the prediction of antigen-antibody interaction kinetics as measured by BIACORE. Protein Eng (2002) 0.85
Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C terminus. Tumour Biol (2012) 0.85
Influence of nuclides and chelators on imaging using affibody molecules: comparative evaluation of recombinant affibody molecules site-specifically labeled with ⁶⁸Ga and ¹¹¹In via maleimido derivatives of DOTA and NODAGA. Bioconjug Chem (2013) 0.84
Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels. Eur J Nucl Med Mol Imaging (2010) 0.84
Biological response to radiation therapy. Acta Oncol (2003) 0.84
Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging. Eur J Nucl Med Mol Imaging (2009) 0.84